Botulinum toxin-A for the treatment of Trigeminal neuralgia
Keywords:
Trigeminal neuralgia, Botulinum toxin-A, BoNT-A, BotoxAbstract
Trigeminal neuralgia (TN) or an inflammation of the trigeminal nerve is one of the most common facial pain syndromes among patients seeing the dentists. Patients generally suffer from severe pain on one side of their faces. Symptom was sharp shooting pain similar to an electric shock or a burning sensation in the facial region that is innervated by one of the branches of the trigeminal nerve (cranial nerve V). Most patients tend to have a trigger zone which is frequently stimulated by their daily activities; lightly touching, cleansing faces, brushing teeth or chewing food. However, these symptoms might occasionally appear on their own without any stimuli.
The first treatment option is drug therapy by using Carbamazepine, one of the long-established first-line drugs used as an anticonvulsant. However, some patients will start drug resistance after short term use, some may be unable to cope with drug-related side effects. One of alternatives treatment is known as botulinum toxin-A (BoNT-A). This has a significant level of therapeutic effect and is considered safe for use.
References
Lambru G, Zakrzewska J, Matharu M. Trigeminal neuralgia: a practical guide. Pract Neurol 2021; 21(5): 392–402.
Bendtsen L, Zakrzewska JM, Heinskou TB, Hodaie M, Leal PRL, Nurmikko T, et al. Advances in diagnosis, classification, pathophysiology, and management of trigeminal neuralgia. Lancet Neurol 2020; 19(9):784-796.
Araya EI, Claudino RF, Piovesan EJ, Chichorro JG. Trigeminal Neuralgia: Basic and Clinical Aspects. Curr Neuropharmacol 2020; 18(2): 109-119.
Maarbjerg S, Di Stefano G, Bendtsen L, CruccuG.. Trigeminal neuralgia - diagnosis and treatment. Cephalalgia 2017; 37(7): 648-657.
Di Stefano G, Truini A, Cruccu G. Current and Innovative Pharmacological Options to Treat Typical and Atypical Trigeminal Neuralgia. Drugs 2018; 78(14): 1433-1442.
Obermann M. Recent advances in understanding/managing trigeminal neuralgia. F1000Res 2019; 17(8): 505-513.
Kim SY, Kim YK, Yun PY, Bae JH. Treatment of non-odontogenic orofacial pain using botulinum toxin-A: a retrospective case series study. Maxillofac Plast Reconstr Surg 2018; 40(1): 21.
Devriese PP. On the discovery of Clostridium botulinum. J Hist Neurosci 1999; 8(1): 43-50.
Brooks VB. The action of botulinum toxin on motor-nerve filaments. J Physiol 1954; 123(3): 501–515.
Scott AB, Schantz E. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 1980; 87: 1044–9.
Micheli F, Scorticati MC, Raina G. Beneficial effects of botulinum toxin type a for patients with painful tic convulsif. Clin Neuropharmacol 2002; 25: 260–262.
Sandrini G, Icco R, Tassorelli, Smania N, Tamburin S. Botulinum neurotoxin type A for the treatment of pain: not just in migraine and trigeminal neuralgia. J Headache Pain 2017; 18(1): 38.
Park J, Chung ME. Botulinum Toxin for Central Neuropathic Pain. Toxins (Basel) 2018; 10(6): 224.
Chávez-Pérez V, Felipe-Spada N, Roldán-Cubero J, Freire-Nieto P, Tomàs-Aliberas J. Current status of the application of botulinum toxin as a treatment option for trigeminal neuralgia. Cranio 2021; 39(1): 1-3.
Verma G. Role of Botulinum Toxin Type-A (BTX-A) in the Management of Trigeminal Neuralgia. Pain Res Treat 2013; 3(10): 94-100.
Muñoz Lora VRM, Del Bel Cury AA, Jabbari B, Lacković Z. Botulinum Toxin Type A in Dental Medicine. J Dent Res 2019; 98(13): 1450-1457.
Li S, Lian YJ, Chen Y, Zhang HF, Ma YQ, He CH, et al. Therapeutic effect of botulinum toxin-A in 88 patients with trigeminal neuralgia with 14-month follow-up. J Headache Pain 2014; 15-43.
Turk U, Duman A, Boluk C, CoşkunDuman S, Taşdemir M. Botulinum toxin in the treatment of trigeminal neuralgia: 6-Month follow-up. Medicine (Baltimore). 2017; 96(39): 8133.
Zhang H, Lian Y, Xie N, Cheng X, Chen C, Xu H, et al. Factors affecting the therapeutic effect of botulinum toxin A on trigeminal neuralgia: A follow-up retrospective study of 152 patients. Exp Ther Med 2019; 18(5): 3375-3382.
Shehata HS, El-Tamawy MS, Shalaby NM, Ramzy G. Botulinum toxin-type A: could it be an effective treatment option in intractable trigeminal neuralgia?. J Headache Pain 2013; 14(1): 92.
Caldera MC, Senanayake SJ, Perera SP, Perera NN, Gamage R, Gooneratne IK. Efficacy of Botulinum Toxin Type A in Trigeminal Neuralgia in a South Asian Cohort. J Neurosci Rural Pract 2018; 9(1): 100-105.
Wu CJ, Lian YJ, Zheng YK, Zhang HF, Chen Y, Xie NC, et al. Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomized, double-blind, placebo-controlled trial. Cephalalgia 2012; 32(6): 443–450.
Meng F, Peng K, Yang JP,Ji FH, Xia F, Meng XW. Botulinum toxin-A for the treatment of neuralgia: a systematic review and meta-analysis. J Pain Res 2018; 11: 2343-2351.
Hu Y, Guan X, Fan L, Li M, Liao Y, Nie Z, et al. Therapeutic efficacy and safety of botulinum toxin type A in trigeminal neuralgia: a systematic review. J Headache Pain 2013; 14(1): 72.
De la Torre Canales G, Poluha RL, Lora VM, Araújo Oliveira Ferreira DM, Stuginski-Barbosa J, Bonjardim LR, et al. Botulinum toxin type A applications for masticatory myofascial pain and trigeminal neuralgia: what is the evidence regarding adverse effects?. Clin Oral Investig 2019; 23(9): 3411-3421.
Zhang H, Lian Y, Ma Y, Chen Y, He C, Xie N, et al. Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial. J Headache Pain 2014; 15(1): 65.
Rubis A, Juodzbalys G. The Use of Botulinum Toxin A in the Management of Trigeminal Neuralgia: a Systematic Literature Review. J Oral Maxillofac Res 2020; 11(2): 2-16.
Piovesan EJ, Teive HG, Kowacs PA, Della Coletta MV, Werneck LC, Silberstein SD. et al. An open study of botulinum-A toxin treatment of trigeminal neuralgia. Neurology 2005; 65(8): 1306-8.
Liu J, Xu YY, Zhang QL, Luo WF. Efficacy and Safety of Botulinum Toxin Type A in Treating Patients of Advanced Age with Idiopathic Trigeminal Neuralgia. Pain Res Manag 2018; 1-5.
Ostrowski H, Roszak J, Komisarek O. Botulinum toxin type A as an alternative way to treat trigeminal neuralgia: a systematic review. Neurol Neurochir Pol 2019; 53(5): 327-334.
Pearl C, Moxley B, Perry A, Demian N, Dallaire-Giroux C. Management of Trigeminal Neuralgia with Botulinum Toxin Type A: Report of Two Cases. Dent J (Basel) 2022; 10(11): 207.
Crespi J, Bratbak D, Dodick DW, Matharu M, Jamtøy KA, Tronvik E. Pilot Study of Injection of Onabotulinum toxin A Toward the Sphenopalatine Ganglion for the Treatment of Classical Trigeminal Neuralgia. Headache 2019; 59(8): 1229-1239.
Wu S, Lian Y, Zhang H, Chen Y, Wu C, Li S, et al. Botulinum Toxin Type A for refractory trigeminal neuralgia in older patients: a better therapeutic effect. J Pain Res 2019; 12: 2177-2186.
Zhang H, Lian Y, Xie N, Chen C, Zheng Y. Single-dose botulinum toxin type a compared with repeated-dose for treatment of trigeminal neuralgia: a pilot study. J Headache Pain 2017; 18(1): 81.
Bohluli B, Motamedi MH, Bagheri SC, Bayat M, Lassemi E, NaviF, et al. Use of botulinum toxin A for drug-refractory trigeminal neuralgia: preliminary report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011; 111(1): 47–50.
Turk U, Ilhan S, Alp R. Botulinum toxin and intractable trigeminal neuralgia. Clin Neuropharmacol 2005; 14: 161–162.
Burmeister J, Holle D, Bock E, Ose C, Diener HC, Obermann M. Botulinum neurotoxin type A in the treatment of classical Trigeminal Neuralgia (BoTN): Study protocol for a randomized controlled trial. Trials 2015; 16: 550.
Serrera - Figallo MA, Ruiz-de-León-Hernández G, Torres-Lagares D, Castro-Araya A, Torres-Ferrerosa O, Hernández-Pacheco E, et al. Use of Botulinum Toxin in Orofacial Clinical Practice. Toxins (Basel) 2020; 12(2): 112.
Wei J, Zhu X, Yang G, Shen J, Xie P, Zuo X, et al. The efficacy and safety of botulinum toxin type A in treatment of trigeminal neuralgia and peripheral neuropathic pain: A meta-analysis of randomized controlled trials. Brain Behav 2019; 9(10): 9-14.
Blitzer A, Binder WJ. Current practices in the use of botulinum toxin A in the manageent of facial lines and wrinkles. Facial Plast Surg Clin North Am 2001; 9(3): 395-404.
Kayani AMA, Silva MS, Jayasinghe M, Singhal M, Karnakoti S, Jain S, et al. Therapeutic Efficacy of Botulinum Toxin in Trigeminal Neuralgia. Cureus 2022; 14(7): 256-268.
Wong HT, Khalil M, Ahmed F. Onabotulinumtoxin A for chronic migraine during pregnancy: a real world experience on 45 patients. J Headache Pain 2020; 21(1): 129.
Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. The New England Journal of Medicine 1991; 324(17): 1186–1194.
Yang DB, Wang ZM, Jiang DY, Chen HC. The efficacy and safety of microvascular decompression for idiopathic trigeminal neuralgia in patients older than 65 years. J Craniofac Surg 2014;25(4):1393-6.
Jorns TP, Ieamsuwantada T , Puttakun P , Tiamkao S , Kitkhuandee A , Noisombut R. Single-Dose Botulinum Toxin as Adjunctive Treatment for Trigeminal Neuralgia: A Pilot Study. J Med Assoc Thai 2019; 102(4): 68.
Laorpipat S, Fuangtharnthip P, Yuma S, Tantipoj C. Attitude of Thai Dental Practitioners towards the Use of Botulinum Toxin in Dentistry. Int J Environ Res Public Health 2022; 19(3): 1878.
Emad M.R., Emad M., Taheri P. The Efficacy of Intradermal Injection of Botulinum Toxin in Patients with Post-Herpetic Neuralgia. Iran Red Crescent Med. J 2011; 13: 323–327.
Breuer B, Sperber K, Wallenstein S, Kiprovski K, Calapa A, Snow B, et al. Clinically significant placebo analgesic response in a pilot trial of botulinum B in patients with hand pain and carpel tunnel syndrome. Pain Med 2006: 7(1): 16-24.
Xia JH, He CH, Zhang HF, Lian YJ, Chen Y, Wu CJ, et al. Botulinum toxin A in the treatment of trigeminal neuralgia. Int J Neurosci 2016; 126(4): 348-53.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
การละเมิดลิขสิทธิ์ถือเป็นความรับผิดชอบของผู้ส่งบทความโดยตรง
ผลงานที่ได้รับการตีพิมพ์ถือเป็นลิขสิทธิ์ของผู้นิพนธ์ ขอสงวนสิทธิ์มิให้นำเนื้อหา ทัศนะ หรือข้อคิดเห็นใด ๆ ของบทความในวารสารไปเผยแพร่ทางการค้าก่อนได้รับอนุญาตจากกองบรรณาธิการ อย่างเป็นลายลักษณ์อักษร
